22,652 Shares of Biogen Inc. $BIIB Bought by Leo Wealth LLC

Leo Wealth LLC purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 22,652 shares of the biotechnology company’s stock, valued at approximately $5,117,000. Biogen comprises 1.1% of Leo Wealth LLC’s holdings, making the stock its 22nd biggest holding.

Other institutional investors also recently added to or reduced their stakes in the company. Apollon Wealth Management LLC boosted its holdings in shares of Biogen by 1,837.4% in the third quarter. Apollon Wealth Management LLC now owns 42,817 shares of the biotechnology company’s stock valued at $9,672,000 after acquiring an additional 40,607 shares during the period. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its position in shares of Biogen by 27.8% during the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 7,913 shares of the biotechnology company’s stock worth $1,787,000 after acquiring an additional 1,720 shares during the last quarter. Kingswood Wealth Advisors LLC grew its position in shares of Biogen by 479.1% during the third quarter. Kingswood Wealth Advisors LLC now owns 9,045 shares of the biotechnology company’s stock worth $2,043,000 after acquiring an additional 7,483 shares during the last quarter. Sigma Planning Corp increased its holdings in shares of Biogen by 100.0% in the 3rd quarter. Sigma Planning Corp now owns 12,385 shares of the biotechnology company’s stock valued at $2,798,000 after acquiring an additional 6,192 shares during the period. Finally, Financial Management Professionals Inc. increased its holdings in shares of Biogen by 5,627.8% in the 3rd quarter. Financial Management Professionals Inc. now owns 1,031 shares of the biotechnology company’s stock valued at $233,000 after acquiring an additional 1,013 shares during the period. Institutional investors and hedge funds own 87.93% of the company’s stock.

Biogen Stock Up 0.6%

BIIB stock opened at $252.26 on Tuesday. The stock has a market capitalization of $37.27 billion, a PE ratio of 44.65, a price-to-earnings-growth ratio of 2.99 and a beta of 0.09. The company has a fifty day moving average of $223.38 and a 200-day moving average of $199.43. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.26 and a current ratio of 1.87. Biogen Inc. has a one year low of $138.00 and a one year high of $254.41.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.94 by $0.66. The business had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The business’s revenue was up 3.4% compared to the same quarter last year. During the same period in the previous year, the business posted $5.47 earnings per share. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, analysts expect that Biogen Inc. will post 12.29 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently commented on BIIB. BMO Capital Markets reiterated a “market perform” rating and issued a $220.00 price target on shares of Biogen in a research report on Monday, October 12th. Weiss Ratings upgraded shares of Biogen from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, September 24th. Citigroup raised their price objective on shares of Biogen from $200.00 to $215.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Wells Fargo & Company raised their price objective on shares of Biogen from $250.00 to $310.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 20th. Finally, Zacks Research upgraded shares of Biogen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Biogen has an average rating of “Moderate Buy” and a consensus target price of $241.89.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.